Oculis Announces Topline Results From Its Phase 2b RELIEF Trial With Licaminlimab, A Novel Anti-Tnfα Biologic Eye Drop
Portfolio Pulse from Benzinga Newsdesk
Oculis announced positive topline results from its Phase 2b RELIEF trial for Licaminlimab, an anti-TNFα biologic eye drop. The trial showed significant improvements in corneal inflammation, especially in patients with the TNFR1 genetic biomarker. The company plans to finalize Phase 3 development plans after an End-of-Phase 2 meeting with the FDA.
June 10, 2024 | 9:13 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Oculis announced positive results from its Phase 2b trial for Licaminlimab, showing significant improvements in corneal inflammation, particularly in patients with the TNFR1 genetic biomarker. The company plans to proceed with Phase 3 development after an FDA meeting.
The positive Phase 2b results and the plan to proceed with Phase 3 development are likely to boost investor confidence and positively impact Oculis' stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100